Table 1 Clinicopathological features of 356 patients who were treated with preoperative chemotherapy
Parameters | All patients (n = 356) (%) | Younger (n = 75) (%) | Elderly (n = 116) (%) |
|---|---|---|---|
Age (years) | 55 (24–78) | 41 (24–45) | 67 (61–78) |
Tumor size (mm) | 28.7 (9.2–119.8) | 29.5 (9.9–82.6) | 27.3 (9.2–89.8) |
Skin infiltration | |||
 Negative/positive | 298 (83.7%)/58 (16.3%) | 68 (90.7%)/7 (9.3%) | 90 (77.6%)/26 (22.4%) |
Lymph node metastasis | |||
 N0/N1/N2/N3 | 121 (33.9%)/133 (37.4%)/68 (19.1%)/34(9.6%) | 28 (37.3%)/28 (37.3%)/14 (18.7%)/5 (6.7%) | 44 (37.9%)/36 (31.0%)/22 (19.0%)/14(12.1%) |
Estrogen receptor | |||
 Negative/positive | 187 (52.5%)/169 (47.5%) | 37 (49.3%)/38 (50.7%) | 67 (57.8%)/49 (42.2%) |
Progesterone receptor | |||
 Negative/positive | 242 (68.0%)/114 (32.0%) | 42 (56.0%)/33 (44.0%) | 89 (76.7%)/27 (23.3%) |
HER2 | |||
 Negative/positive | 231 (64.9%)/125 (35.1%) | 47 (62.7%)/28 (37.3%) | 69 (59.5%)/47 (40.5%) |
Ki67 | |||
 ≤ 14 %/> 14 % | 117 (32.9%)/239 (67.1%) | 22 (29.3%)/53 (70.7%) | 40 (34.5%)/76 (65.5%) |
Intrinsic subtype | |||
 HR+HER2-BC/HR+HER2+BC/HER2BC/TNBC | 126 (35.4%)/47 (13.2%)/78 (21.9%)/105 (29.5%) | 24 (32.0%)/16 (21.3%)/12 (16.0%)/23 (30.7%) | 39 (33.6%)/11 (9.5%)/36 (31.0%)/30 (25.9%) |
Objective response rate | |||
 Non-responders/responders | 40 (11.2%)/316 (88.8%) | 5 (6.7%)/70 (93.3%) | 17 (14.7%)/99 (85.3%) |
Pathological response | |||
 Non-pCR/pCR | 238 (66.9%)/118 (33.1%) | 46 (61.3%)/29 (38.7%) | 78 (67.2%)/38 (32.8%) |
TILs | |||
 Low/high | 195 (54.5%)/161 (45.2%) | 31 (41.3%)/44 (58.7%) | 65 (56.0%)/51 (44.0%) |